- Home
- ADSE vs ATXS Comparison
ADSE vs ATXS Comparison
Compare ADSE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADSE | ATXS |
|---|---|---|
| Founded | 1980 | 2008 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 577.8M | 722.1M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | ADSE | ATXS |
|---|---|---|
| Price | $12.40 | $12.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $24.33 |
| AVG Volume (30 Days) | 26.3K | ★ 1.3M |
| Earning Date | 12-23-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $53,275,396.00 | $706,000.00 |
| Revenue This Year | $219.58 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.89 | $3.56 |
| 52 Week High | $16.35 | $13.29 |
Technical Indicators
Market Signals| Indicator | ADSE | ATXS |
|---|---|---|
| Relative Strength Index (RSI) | 61.65 | 64.63 |
| Support Level | $12.23 | $12.87 |
| Resistance Level | $12.67 | $13.29 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 82.56 | 63.68 |
Price Performance
Historical ComparisonAbout ADSE ADS-TEC ENERGY PLC
ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. ADSE generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.